111 related articles for article (PubMed ID: 22050017)
1. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Procopio G
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
6. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
7. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
8. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
10. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
[TBL] [Abstract][Full Text] [Related]
11. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
16. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
17. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
18. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
19. [Nexavar clinical registry].
Büchler T
Klin Onkol; 2010; 23(4):269-70. PubMed ID: 20806826
[No Abstract] [Full Text] [Related]
20. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
